Squamous Cell Carcinoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 145 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Squamous Cell Carcinoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Squamous Cell Carcinoma - Overview 10
Pipeline Products for Squamous Cell Carcinoma - Comparative Analysis 11
Squamous Cell Carcinoma - Therapeutics under Development by Companies 12
Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 15
Squamous Cell Carcinoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Squamous Cell Carcinoma - Products under Development by Companies 19
Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 21
Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Axelar AB 23
Bexion Pharmaceuticals, LLC. 24
Boehringer Ingelheim GmbH 25
Celgene Corporation 26
Clinuvel Pharmaceuticals Limited 27
Eli Lilly and Company 28
G&E Herbal Biotechnology Co., Ltd. 29
Genextra S.p.a. 30
Genmab A/S 31
Hutchison MediPharma Limited 32
InMed Pharmaceuticals Inc. 33
Karyopharm Therapeutics, Inc. 34
Neotropix, Inc. 35
Omeros Corporation 36
Oncolytics Biotech Inc. 37
Onconova Therapeutics, Inc. 38
Oncovir, Inc. 39
Otsuka Holdings Co., Ltd. 40
Pfizer Inc. 41
Sanofi 42
Squamous Cell Carcinoma - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
afamelanotide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
afatinib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AMXT-1501 + eflornithine hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Antibody Drug Conjugate to Inhibit EFGR for Squamous Cell Tumor and Glioblastoma - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AXL-1717 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
boanmycin hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BXQ-350 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CIGB-128 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CS-S/BCC-1 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CS-TATI-1 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CUV-9900 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DAC-0060 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dacomitinib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HMPL-453 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
LY-2606368 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NTX-500 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
OPB-111001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
paclitaxel albumin bound - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pelareorep - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Poly-ICLC - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
rigosertib sodium - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SAR-408701 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
selinexor - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecule to Antagonize GPR87 for Cancer - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Cancer - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
SRT-100 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
TF-011 Monomethyl Auristatin E - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Squamous Cell Carcinoma - Recent Pipeline Updates 107
Squamous Cell Carcinoma - Dormant Projects 138
Squamous Cell Carcinoma - Discontinued Products 139
Squamous Cell Carcinoma - Product Development Milestones 140
Featured News & Press Releases 140
Sep 27, 2014: Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung 140
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 141
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 142
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma 142
Mar 30, 2010: Oncolytics Announces Start Of Enrollment In US Phase II SCC Lung Cancer Trial 143
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 145
Disclaimer 145

List of Tables
Number of Products under Development for Squamous Cell Carcinoma, H2 2014 10
Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H2 2014 22
Squamous Cell Carcinoma - Pipeline by Axelar AB, H2 2014 23
Squamous Cell Carcinoma - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014 24
Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 25
Squamous Cell Carcinoma - Pipeline by Celgene Corporation, H2 2014 26
Squamous Cell Carcinoma - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014 27
Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 28
Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 29
Squamous Cell Carcinoma - Pipeline by Genextra S.p.a., H2 2014 30
Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2014 31
Squamous Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2014 32
Squamous Cell Carcinoma - Pipeline by InMed Pharmaceuticals Inc., H2 2014 33
Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 34
Squamous Cell Carcinoma - Pipeline by Neotropix, Inc., H2 2014 35
Squamous Cell Carcinoma - Pipeline by Omeros Corporation, H2 2014 36
Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2014 37
Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2014 38
Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H2 2014 39
Squamous Cell Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 40
Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014 41
Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Assessment by Combination Products, H2 2014 44
Number of Products by Stage and Target, H2 2014 46
Number of Products by Stage and Mechanism of Action, H2 2014 49
Number of Products by Stage and Route of Administration, H2 2014 52
Number of Products by Stage and Molecule Type, H2 2014 54
Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 107
Squamous Cell Carcinoma - Dormant Projects, H2 2014 138
Squamous Cell Carcinoma - Discontinued Products, H2 2014 139